This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoymans, V. Y.
Right arrow Articles by Ieven, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoymans, V. Y.
Right arrow Articles by Ieven, M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2003, p. 4049-4053, Vol. 41, No. 9
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.9.4049-4053.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Importance of Methodology in Determination of Chlamydia pneumoniae Seropositivity in Healthy Subjects and in Patients with Coronary Atherosclerosis

V. Y. Hoymans,1* J. M. Bosmans,1 L. Van Renterghem,2 R. Mak,3 D. Ursi,4 F. Wuyts,5 C. J. Vrints,1 and M. Ieven4

Departments of Cardiology,1 Microbiology,4 Medical Statistics, University of Antwerp, Edegem,5 Departments of Bacteriology and Virology,2 Public Health, Ghent University Hospital, Ghent, Belgium3

Received 25 November 2002/ Returned for modification 18 January 2003/ Accepted 4 April 2003

Enzyme immunoassays (EIAs) for the detection of Chlamydia pneumoniae antibodies were compared to the microimmunofluorescence (MIF) test, the reference method. Furthermore, we assessed the hypothesis that a possible relationship between Chlamydia pneumoniae immunoglobulin G (IgG) antibodies and coronary artery disease is dependent on the type of EIA. Sera from 112 healthy men (mean age, 50.1 years) were tested for antibodies against Chlamydia pneumoniae by five commercial test kits: Focus Chlamydia MIF IgG test, Labsystems Chlamydia pneumoniae IgG EIA (LS EIA), R-Biopharm Elegance Chlamydia pneumoniae IgG EIA (RB EIA), Medac Chlamydia pneumoniae IgG sandwich enzyme-linked immunosorbent assay ELISA (MCp sELISA) and Medac Chlamydia IgG recombinant enzyme-linked immunosorbent assay ELISA (MC rELISA). Sera from 106 consecutive male patients (mean age, 63.6 years) undergoing diagnostic coronary angiography were also examined using the Focus MIF, LS EIA, MCp sELISA, and MC rELISA techniques. The agreement between LS EIA (65 to 83% [controls-patients]) or MC rELISA (49 to 61%) and Focus MIF (78 to 83%) was average to fair ({kappa} = 0.597 and 0.234, respectively). MCp sELISA and RB EIA showed good agreement with MIF ({kappa} = 0.686 and 0.665, respectively), with 80 to 89 and 79% of individuals reacting positively. A significant difference in seroprevalence between patients and healthy subjects was observed with the LS EIA, while seropositivities in the two study groups appeared equal when the Focus MIF assay was applied. The MC rELISA and MCp sELISA gave statistically significant differences in antibody seroprevalence in patients with two-vessel disease or when the patient group combined individuals with a two- or a three-vessel disease, respectively. The concordance between MIF and other commonly used serological assays for C. pneumoniae IgG antibody detection is good to fair. The choice of serological assay has important implications for C. pneumoniae antibody seroprevalence, as well as for the relationship between C. pneumoniae seropositivity and coronary artery disease.

* Corresponding author. Mailing address: Department of Cardiology, University Hospital Antwerp/University of Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium. Phone: 32 38214946. Fax: 32 38302305. E-mail: vicky.hoymans{at}uza.be.

Journal of Clinical Microbiology, September 2003, p. 4049-4053, Vol. 41, No. 9
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.9.4049-4053.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Loens, K., Van Heirstraeten, L., Malhotra-Kumar, S., Goossens, H., Ieven, M. (2009). Optimal Sampling Sites and Methods for Detection of Pathogens Possibly Causing Community-Acquired Lower Respiratory Tract Infections. J. Clin. Microbiol. 47: 21-31 [Full Text]  
  • Diederen, B. M. W., van der Valk, P. D. L. P. M., Kluytmans, J. A. W. J., Peeters, M. F., Hendrix, R. (2007). The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur Respir J 30: 240-244 [Abstract] [Full Text]  
  • Nishimura, M., Hashimoto, T., Kobayashi, H., Fukuda, T., Okino, K., Yamamoto, N., Mashida, C., Kawagoe, K., Fujita, H., Inoue, N., Takahashi, H., Ono, T. (2005). Close association of Chlamydia pneumoniae IgA seropositivity by ELISA with the presence of coronary artery stenosis in haemodialysis patients. Nephrol Dial Transplant 20: 1944-1950 [Abstract] [Full Text]  
  • Paldanius, M., Bloigu, A., Alho, M., Leinonen, M., Saikku, P. (2005). Prevalence and Persistence of Chlamydia pneumoniae Antibodies in Healthy Laboratory Personnel in Finland. CVI 12: 654-659 [Abstract] [Full Text]  
  • Ieven, M. M., Hoymans, V. Y. (2005). Involvement of Chlamydia pneumoniae in Atherosclerosis: More Evidence for Lack of Evidence. J. Clin. Microbiol. 43: 19-24 [Full Text]  
  • Ieven, M. M., Hoymans, V. Y., Bosmans, J. M., Sander, D., Winbeck, K., Klingelhofer, J., Etgen, T., Conrad, B. (2004). Early Carotid Atherosclerosis and Chlamydia pneumoniae Seropositivity: Are There Arguments to Treat With Antibiotics? * Response. Circulation 110: e74-e75 [Full Text]  
  • Maraha, B., den Heijer, M., Kluytmans, J., Peeters, M. (2004). Impact of Serological Methodology on Assessment of the Link between Chlamydia pneumoniae and Vascular Diseases. CVI 11: 789-791 [Abstract] [Full Text]  
  • Hoymans, V. Y., Bosmans, J. M., Ursi, D., Martinet, W., Wuyts, F. L., Van Marck, E., Altwegg, M., Vrints, C. J., Ieven, M. M. (2004). Immunohistostaining Assays for Detection of Chlamydia pneumoniae in Atherosclerotic Arteries Indicate Cross-Reactions with Nonchlamydial Plaque Constituents. J. Clin. Microbiol. 42: 3219-3224 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»